278 related articles for article (PubMed ID: 29845708)
21. Polycomb repressor complex: Its function in human cancer and therapeutic target strategy.
Liu J; Fan H; Liang X; Chen Y
Biomed Pharmacother; 2023 Dec; 169():115897. PubMed ID: 37981459
[TBL] [Abstract][Full Text] [Related]
22. The polycomb proteins EZH1 and EZH2 co-regulate chromatin accessibility and nephron progenitor cell lifespan in mice.
Liu H; Hilliard S; Kelly E; Chen CH; Saifudeen Z; El-Dahr SS
J Biol Chem; 2020 Aug; 295(33):11542-11558. PubMed ID: 32554463
[TBL] [Abstract][Full Text] [Related]
23. EZH2 in normal and malignant hematopoiesis.
Lund K; Adams PD; Copland M
Leukemia; 2014 Jan; 28(1):44-9. PubMed ID: 24097338
[TBL] [Abstract][Full Text] [Related]
24. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Wen Y; Cai J; Hou Y; Huang Z; Wang Z
Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
[TBL] [Abstract][Full Text] [Related]
25. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
27. Roles of enhancer of zeste homolog 2: from skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis.
Marchesi I; Giordano A; Bagella L
Cell Cycle; 2014; 13(4):516-27. PubMed ID: 24496329
[TBL] [Abstract][Full Text] [Related]
28. Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors.
Chen F; Byrd AL; Liu J; Flight RM; DuCote TJ; Naughton KJ; Song X; Edgin AR; Lukyanchuk A; Dixon DT; Gosser CM; Esoe DP; Jayswal RD; Orkin SH; Moseley HNB; Wang C; Brainson CF
Nat Commun; 2023 Jan; 14(1):336. PubMed ID: 36670102
[TBL] [Abstract][Full Text] [Related]
29. JARID2 and EZH2, the eminent epigenetic drivers in human cancer.
Sreeshma B; Devi A
Gene; 2023 Aug; 879():147584. PubMed ID: 37353042
[TBL] [Abstract][Full Text] [Related]
30. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
31. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
[TBL] [Abstract][Full Text] [Related]
32. Deletion of the Polycomb-Group Protein EZH2 Leads to Compromised Self-Renewal and Differentiation Defects in Human Embryonic Stem Cells.
Collinson A; Collier AJ; Morgan NP; Sienerth AR; Chandra T; Andrews S; Rugg-Gunn PJ
Cell Rep; 2016 Dec; 17(10):2700-2714. PubMed ID: 27926872
[TBL] [Abstract][Full Text] [Related]
33. EZH2 in normal hematopoiesis and hematological malignancies.
Herviou L; Cavalli G; Cartron G; Klein B; Moreaux J
Oncotarget; 2016 Jan; 7(3):2284-96. PubMed ID: 26497210
[TBL] [Abstract][Full Text] [Related]
34. Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
Pyziak K; Sroka-Porada A; Rzymski T; Dulak J; Łoboda A
Drug Dev Res; 2021 Sep; 82(6):730-753. PubMed ID: 33565092
[TBL] [Abstract][Full Text] [Related]
35. EZH1/2 as targets for cancer therapy.
An R; Li YQ; Lin YL; Xu F; Li MM; Liu Z
Cancer Gene Ther; 2023 Feb; 30(2):221-235. PubMed ID: 36369341
[TBL] [Abstract][Full Text] [Related]
36. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
37. Double sword role of EZH2 in leukemia.
Safaei S; Baradaran B; Hagh MF; Alivand MR; Talebi M; Gharibi T; Solali S
Biomed Pharmacother; 2018 Feb; 98():626-635. PubMed ID: 29289837
[TBL] [Abstract][Full Text] [Related]
38. PRC2 specifies ectoderm lineages and maintains pluripotency in primed but not naïve ESCs.
Shan Y; Liang Z; Xing Q; Zhang T; Wang B; Tian S; Huang W; Zhang Y; Yao J; Zhu Y; Huang K; Liu Y; Wang X; Chen Q; Zhang J; Shang B; Li S; Shi X; Liao B; Zhang C; Lai K; Zhong X; Shu X; Wang J; Yao H; Chen J; Pei D; Pan G
Nat Commun; 2017 Sep; 8(1):672. PubMed ID: 28939884
[TBL] [Abstract][Full Text] [Related]
39. EZH1 in germ cells safeguards the function of PRC2 during spermatogenesis.
Mu W; Starmer J; Shibata Y; Yee D; Magnuson T
Dev Biol; 2017 Apr; 424(2):198-207. PubMed ID: 28254491
[TBL] [Abstract][Full Text] [Related]
40. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms.
Margueron R; Li G; Sarma K; Blais A; Zavadil J; Woodcock CL; Dynlacht BD; Reinberg D
Mol Cell; 2008 Nov; 32(4):503-18. PubMed ID: 19026781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
